Assessment and comparison of adverse drug reactions reporting by USFDA and CDSCO: an audit
DOI:
https://doi.org/10.18203/2349-3259.ijct20261381Keywords:
Safety communications, Alerts, PVPI, USFDAAbstract
Background: Drug safety is a critical component not only during the development of pharmaceutical products but also throughout their post-marketing lifecycle. Pharmacovigilance systems play a vital role in monitoring and evaluating adverse drug reactions (ADRs), with many national programs contributing data to the World Health Organization’s Pharmacovigilance Programme headquartered in Uppsala, Sweden.
Methods: The present study aimed to assess and compare ADR reports submitted by various stakeholders in the United States and India. Publicly available pharmacovigilance data from both countries were systematically reviewed and analysed, excluding information related to dyes, medical devices, and blood-related products.
Results: The comparison indicated that the United States Food and Drug Administration (USFDA) receive a substantially higher number of ADR reports compared to India. However, the number of safety alerts issued over the past four years appears to be relatively consistent between the two countries. Antibacterial agents and drugs acting on the endocrine system were among the most frequently reported therapeutic categories.
Conclusions: This study highlights differences in reporting trends and underscores the need for strengthening ADR reporting mechanisms to enhance drug safety monitoring.
References
WHO. Pharmacovigilance. Available at: https://www.who.int/teams/regulationprequalification/regulation-and-safety/pharmacovigilance. Accessed on 05 January 2026.
U.S. Food and Drug Administration. Drug Safety Communications. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications. Accessed on 05 January 2026.
Boora P, Kumar PR, Chandra PH. Pharmacovigilance in India and Its Challenges. J Pharmacovigil. 2022;10:379.
Pharmacovigilance Program of India. Available at https://www.ipc.gov.in/. Last accessed on 02nd January 2026.
Indian Pharmacopoeia Commission. Annual performance reports. Available at: https://www.ipc.gov.in/mandates/pvpi/publications/8-category-en/646-annual-performance-report.html. Accessed on 05 January 2026.
Centers for Disease Control and Prevention. Therapeutic drug use. Atlanta (GA): Centers for Disease Control and Prevention. 2023. Available at https://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm. Accessed on 05 Jan 2026.
IQVIA Institute for Human Data Science. Understanding the Use of Medicines in the U.S. 2025 — data showing continuing growth in prescription and chronic medication use. 2025. Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/ understanding-the-use-of-medicines-in-the-us-2025. Accessed on 05 January 2026
U.S. Congressional Research Service. Specialty Drugs: Background and Policy Concerns. Washington (DC): Congressional Research Service. 2025. Available at: https://www.congress.gov/crs-product/R44132#_Toc427846470. Accessed on 05 January 2026.
Gupta SK, Nayak RP, Shivaranjani R. Adverse drug reaction reporting in India: Past, present and future. J Pharmacol Pharmacother. 2015;6(2):87-92.
Tripathi A. Adverse drug reaction reporting patterns in Indian pharmacovigilance. J Adv Agric Food Res. 2022;25(1):228-34.
Reddy VL, Pasha SJ, Rathinavelu M, Reddy YP. Assessment of adverse drug reaction reporting culture in Pharmacovigilance Programme of India. Indian J Med Res. 2014;139(4):563-70.
Downloads
Published
How to Cite
Issue
Section
